12/09/2012 - General information
The project- based on a collaboration agreement between the Barcelona Science Park (PCB) and the companies SOM Biotech and Metasbio– will enable the discovery of new therapeutic applications of previously existing drugs (repurposing), especially in areas of great medical need and market potential, such as the central nervous system, oncology and orphan diseases.
25/07/2012 - Press release
Researchers from IMIM have deciphered the function executed by a protein called ?-catenin in generating blood tissue stem cells. These cells, also called haematopoietic, are used as a source for transplants that form part of the therapies to fight different types of leukaemia. The results obtained will open the doors to produce these stem cells in the laboratory and, thus, improve the quality and quantity of these surgical procedures. This will let patients with no compatible donors be able to benefit from this discovery in the future.
23/07/2012 - General information
From the 27th of July until the 12th of August the London 2012 Olympics will be taking place. Once again, and thanks to an agreement between King’s College in London and the IMIM Foundation, as of the 23rd of July a group of technicians from the IMIM Bioanalysis and Analysis Services research group will join the Official Antidoping Laboratory of the London 2012 Olympics.
Més informació "The IMIM Antidoping Control Lab in London 2012"
21/06/2012 - General information
"Connect, partner and innovate". This is the slogan for the twentieth edition of the BIO International Convention, held 18 to 21 June 2012 in the city of Boston (Massachusetts, United States). BIO is the most important international business meeting in the biotechnology arena. This year, it will bring together more than 15,000 delegates from 65 countries, more than 900 exhibitors and 1,800 companies. In addition to the exhibition area, it also features a Business Forum for partnering meetings, which in 2011 generated more than 21,000 one-to-one meetings.
Més informació "GRIB participated at BIO Boston 2012, the top biotechnology convention in the world"
19/06/2012 - Press release
Researchers at the IMIM (Institut de Recerca Hospital del Mar) have proven that the absence of the 14-3-3 protein sigma in breast cancer cells is directly associated with these cells’ capacity to activate the signalling of a protein complex called NF-kB, which is related to tumour progression. The activation of NF-kB in tumours was also identified as the best indicator for relapse in breast cancer patients, compared to other parameters currently used, such as the presence of affected ganglions or the tumour’s size and degree.
Més informació "A new indicator for breast cancer relapse identified"
24/05/2012 - Press release
Researchers at the IMIM (Hospital del Mar Research Institute) and the Hospital del Mar have studied the role of NK cells in the development and progression of Chronic Obstructive Pulmonary Disease (COPD) when a viral infection is present. The results from the study show that these cells play a decisive role in the natural progression of the disease.
Més informació "New Indicators to Reveal the Progression of COPD"
21/05/2012 - General information
After one week of intensive training, the closing event of the INBIOMEDvision Training Challenge successfully took place in Barcelona. This training gathered together two teams of 5 PhD students with different nationalities and scientific backgrounds (chemists, medical doctors, informatics, mathematics, biologists etc.) to work on two case studies related with health sciences during one week at the Monastery of Les Avellanes (Lleida, Spain).
17/05/2012 - Press release
An international collaborative study with the participation of researchers from the IMIM (Hospital del Mar Research Institute), has studied whether the link between the levels of HDL cholesterol, commonly called “good cholesterol” and the risk of suffering an acute myocardial infarction is or isn’t causal, by using genetic biomarkers. The article will be published in the prestigious Lancet journal.
08/05/2012 - Press release
A group of researchers from the IMIM (Hospital del Mar Research Institute) and from the INAD (Hospital del Mar Neuropsychiatry and Addictions Institute) has participated in an international study aiming to give a general overview at a chemical, pharmacological and behavioural level of a recently appeared new chemical compound, according to the Recreational Drugs European Network, as a new abused drug: methoxetamine (MXE).
Més informació "Internet and new drugs: a challenge for Public Health"
27/04/2012 - Press release
Yesterday, Thursday 26 April, saw the conclusion in Barcelona of the first edition of GRIB EXPO, a symposium organised by the Research Programme on Biomedical Informatics (GRIB), a joint research group of the IMIM (Hospital del Mar Research Institute) and Pompeu Fabra University (UPF). The aim of the EXPO was to bring Biomedical Informatics closer to the clinical sector and to industrial innovation, with a view to promoting the open exchange of ideas and cooperation.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
